Wow pretty good impact, especially since the trial results were good, but not exactly a slam dunk.

"Twelve patients on Epidiolex discontinued treatment due to adverse events compared with one patient on placebo. There was one death in the Epidiolex group, which was deemed unrelated to treatment. Of the patients who completed this trial, 100 percent have opted to continue into an open-label extension trial."

http://www.streetinsider.com/dr/news.php?id=11774535